This will inform future discussions and funding applications for collaborative UK cardio-oncology research. For further information, please contact [email protected].
Please take 10 minutes to complete this short survey (https://t.co/NHvVQgzQBf), which seeks to gain an overview of opinions from UK-based healthcare professionals in relation to cardio-oncology research priorities.
The PROACT trial found adding enalapril to standard care during chemotherapy did not prevent cardiotoxicity in patients receiving high-dose anthracycline-based chemotherapy.
Read more on the trial: https://t.co/WPIPe6UM8N #ACCLATAM
We are highlighting the sessions you can expect at BSEcho 2024 - we're excited to see you in Edinburgh!
See the programme for our cardio-oncology session in association with @BCOSCardioOnc
👇 View the full programme and book on our website: https://t.co/Vw1lO2C7VN
This joint @BritishCardioSo@BCOSCardioOnc and @UCLH Cancer Academy course will give the attendee an update in contemporary cardio-oncology practice and will cover recent updates in cardio-oncology.
https://t.co/LOJsWWVk63
#GCOS2024 is going to be packed with talks from leading voices around the world including @BlaesAnneMD, Dr Alexander Lyon, Dr Bonnie Ky, and many more.
See the Full Lineup: https://t.co/wlDT9RaF6U
Don't miss out - save your spot: https://t.co/62Rglzsgzy
#cardioonc
In this #JACCCardioOnc review, Dr. @DavidGGent, et al cover the breadth of what is known about #CVD in the adult #HCT population, focusing on acute & late complications, risk prediction, surveillance, & treatment of complications. https://t.co/khVvFpz3dE #CardioOnc
Food for thought. Are the historical anthracycline conversion ratios still appropriate for use in contemporary clinical practice and research?
https://t.co/rjqFDLTKQR
SCE (HF, cardiogenic shock or MI) in 16% & ☠️ in 53% at last f/u.
SCE associated w/ ⬆️ overall mortality (HR 2.8; 95% CI 1.6 - 4.7) and non-relapse mortality (HR 3.5; 95% CI 1.4 - 8.8).
☠️ associated w/ ⬆️ IL-6 and ferritin after CAR-T, SCE also associated w/ ⬆️ CRP & trop.
10. Biomarkers and cardiovascular outcomes in CAR T-cell therapy recipients
❓Multi-centre registry study examining the association between CAR-T related severe CV events (SCE) and mortality.
🏥202 patients w/ anti-CD19 CAR-T, median f/u 297 days.
https://t.co/jlow77Qk8Y